Hat mitgewirkt an:
-
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
-
Numeracy of multiple sclerosis patients : A comparison of patients from the PERCEPT study to a German probabilistic sample
-
Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients
-
Apheresis therapies for NMOSD attacks : a retrospective study of 207 therapeutic interventions